Miro clears TGA audit ahead of Crohn’s disease trial

Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.

First reported by The Sydney Morning Herald 26 min ago1 source

Read at The Sydney Morning Herald

Full coverage

Every report we found on this story, oldest first. Each links to the original publisher.

The Sydney Morning Herald01:2426 min ago
Miro clears TGA audit ahead of Crohn’s disease trial (opens The Sydney Morning Herald in a new tab)
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.

Something wrong with how we've grouped or summarised this story? Report a problem